For four years the official line on ivermectin in the United States held that the drug was, depending on the speaker, “horse paste,” dangerous, ineffective and unworthy of serious clinical attention. That line has begun, very quietly, to bend.
A prospective observational cohort published 7 April 2026 on the open repository Zenodo reports real-world clinical outcomes for cancer patients self-administering ivermectin and the related antiparasitic mebendazole. The authors, drawing on patient-reported data across multiple months of follow-up, document signals of symptom improvement and quality-of-life benefit across several tumour types. The paper is hypothesis-generating – it carries the limitations of observational design, self-reporting and probable selection bias – but it is the first study in this category to clear peer-review and indexing in the post-COVID era.
It does not stand alone. STAT News reported in February that the United States National Cancer Institute is “taking ivermectin seriously” and has commenced preclinical work to evaluate the drug’s anti-tumour mechanisms. The Williams Cancer Institute has separately documented patient pathways involving ivermectin alongside conventional regimens. PubMed-indexed reviews from late 2025 and 2026 catalogue the drug’s documented effects on cancer-cell apoptosis, proliferation, autophagy and signalling pathways across breast, leukaemia, ovarian, melanoma and colorectal lines.
The Mockery That Aged Badly
The vocabulary used to dismiss ivermectin during the COVID era – “horse paste,” “Joe Rogan drug,” “killing themselves” – was deployed not by random online commenters but by network anchors, late-night hosts, government health officials and the editorial pages of the largest newspapers in the English-speaking world. The drug, awarded the 2015 Nobel Prize in Medicine for its parasitic indication, had a clinical safety record stretching across billions of human doses. Its antiviral and immunomodulatory properties were documented in the peer-reviewed literature long before COVID.
The mockery was not, in retrospect, a scientific position. It was a media position. The same pharmaceutical corridors that funded the loudest dismissive coverage are now positioning around the molecule’s potential cancer indication.
What’s Different This Time
The paper has cleared the gate – on Zenodo, but with peer-review and a citable DOI. The NCI is engaged on the record. Oncologists who two years ago would not say the word in public are now using it in conference panels with caveats about “ongoing studies.” The drug is also off-patent and cheap, which is part of why it is interesting and part of why it has been so difficult to study within the existing clinical-trial economy.
The mainstream press, when it covers the story, frames it with strict caution – “evidence remains limited,” “not approved for cancer,” “consult your oncologist.” All of which is true. None of which addresses the more uncomfortable question – how much earlier might the work have begun, and how many patients might have benefited, had the molecule not been turned into a cultural punchline by the same institutions now studying it.
